KIAA0247 Suppresses the Proliferation, Angiogenesis and Promote Apoptosis of Human Glioma Through Inactivation of the AKT and Stat3 Signaling Pathway

Overview

Journal Oncotarget

Specialty Oncology

Date 2016 Nov 29

PMID 27893430

Citations 12

Authors

Ying Tan

Ning Huang

Xiang Zhang

Jiangang Hu

Si Cheng

Li Pi

Yuan Cheng

Affiliations

Soon will be listed here.

Abstract

Gliomas are the most common and aggressive type of primary adult brain tumors. Although KIAA0247 previously is a speculated target of the tumor suppressor gene, little is known about the association between KIAA0247 and glioma. In this study, we clearly demonstrate that KIAA0247 expression is decreased in glioma and was negatively correlated with the histologic grade. Overexpression of KIAA0247 in glioma cells inhibits proliferation, angiogenesis and promoted apoptosis of human glioma cells in vitro. In contrast, knockdown of KIAA0247 increases the proliferation, angiogenesis and decreases apoptosis of these cells. In a tumor xenograft model, overexpression of KIAA0247 suppresses tumor growth of glioma cells in vivo, while KIAA0247 knockdown promotes the tumor growth. Mechanistically, overexpression of KIAA0247 is able to inhibit phosphorylation of AKT and Stat3 in glioma cells, resulting in inactivation of the AKT and Stat3 signaling pathways, this ultimately decreases the expression of PCNA, CyclinD1, Bcl2 and VEGF. Collectively, these data indicate that KIAA0247 may work as a tumor suppressor gene in glioma and a promising therapeutic target for gliomas.

Citing Articles

miR-451 suppresses EMT and metastasis in glioma cells.

Nan Y, Guo L, Lu Y, Guo G, Hong R, Zhao L Cell Cycle. 2021; 20(13):1270-1278.

PMID: 34048322 PMC: 8331032. DOI: 10.1080/15384101.2021.1933303.

Puma- and Caspase9-mediated apoptosis is dispensable for p53-driven neural crest-based developmental defects.

Bowen M, Mulligan A, Sorayya A, Attardi L Cell Death Differ. 2021; 28(7):2083-2094.

PMID: 33574585 PMC: 8257737. DOI: 10.1038/s41418-021-00738-7.

MicroRNA miR-100 Decreases Glioblastoma Growth by Targeting SMARCA5 and ErbB3 in Tumor-Initiating Cells.

Alrfaei B, Clark P, Vemuganti R, Kuo J Technol Cancer Res Treat. 2020; 19:1533033820960748.

PMID: 32945237 PMC: 7502994. DOI: 10.1177/1533033820960748.

Glutamine affects T24 bladder cancer cell proliferation by activating STAT3 through ROS and glutaminolysis.

Sun N, Liang Y, Chen Y, Wang L, Li D, Liang Z Int J Mol Med. 2019; 44(6):2189-2200.

PMID: 31661119 PMC: 6844601. DOI: 10.3892/ijmm.2019.4385.

Gene-Specific Intron Retention Serves as Molecular Signature that Distinguishes Melanoma from Non-Melanoma Cancer Cells in Greek Patients.

Giannopoulou A, Konstantakou E, Velentzas A, Avgeris S, Avgeris M, Papandreou N Int J Mol Sci. 2019; 20(4).

PMID: 30795533 PMC: 6412294. DOI: 10.3390/ijms20040937.

References

Landowski T, Oshiro M, Turkson J, Levitzki A, Savino R, Ciliberto G . Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity. 1999; 10(1):105-15. DOI: 10.1016/s1074-7613(00)80011-4. View

Bromberg J, Wrzeszczynska M, Devgan G, Zhao Y, Pestell R, Albanese C . Stat3 as an oncogene. Cell. 1999; 98(3):295-303. DOI: 10.1016/s0092-8674(00)81959-5. View

Madrid L, Wang C, Guttridge D, Schottelius A, Baldwin Jr A, Mayo M . Akt suppresses apoptosis by stimulating the transactivation potential of the RelA/p65 subunit of NF-kappaB. Mol Cell Biol. 2000; 20(5):1626-38. PMC: 85346. DOI: 10.1128/MCB.20.5.1626-1638.2000. View

Robles A, Bemmels N, Foraker A, Harris C . APAF-1 is a transcriptional target of p53 in DNA damage-induced apoptosis. Cancer Res. 2001; 61(18):6660-4. View

Sonoda Y, Ozawa T, Aldape K, Deen D, Berger M, Pieper R . Akt pathway activation converts anaplastic astrocytoma to glioblastoma multiforme in a human astrocyte model of glioma. Cancer Res. 2001; 61(18):6674-8. View

Shin I, Yakes F, Rojo F, Shin N, Bakin A, Baselga J . PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization. Nat Med. 2002; 8(10):1145-52. DOI: 10.1038/nm759. View

Kandel E, Skeen J, Majewski N, Di Cristofano A, Pandolfi P, Feliciano C . Activation of Akt/protein kinase B overcomes a G(2)/m cell cycle checkpoint induced by DNA damage. Mol Cell Biol. 2002; 22(22):7831-41. PMC: 134727. DOI: 10.1128/MCB.22.22.7831-7841.2002. View

Rahaman S, Harbor P, Chernova O, Barnett G, Vogelbaum M, Haque S . Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells. Oncogene. 2002; 21(55):8404-13. DOI: 10.1038/sj.onc.1206047. View

Konnikova L, Kotecki M, Kruger M, Cochran B . Knockdown of STAT3 expression by RNAi induces apoptosis in astrocytoma cells. BMC Cancer. 2003; 3:23. PMC: 212316. DOI: 10.1186/1471-2407-3-23. View

10.

Siegel P, Massague J . Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer. 2003; 3(11):807-21. DOI: 10.1038/nrc1208. View

11.

Staib F, Robles A, Varticovski L, Wang X, Zeeberg B, Sirotin M . The p53 tumor suppressor network is a key responder to microenvironmental components of chronic inflammatory stress. Cancer Res. 2005; 65(22):10255-64. PMC: 1421332. DOI: 10.1158/0008-5472.CAN-05-1714. View

12.

van den Bent M, Hegi M, Stupp R . Recent developments in the use of chemotherapy in brain tumours. Eur J Cancer. 2006; 42(5):582-8. DOI: 10.1016/j.ejca.2005.06.031. View

13.

Iwamaru A, Szymanski S, Iwado E, Aoki H, Yokoyama T, Fokt I . A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene. 2006; 26(17):2435-44. DOI: 10.1038/sj.onc.1210031. View

14.

Koseoglu S, Lu Z, Kumar C, Kirschmeier P, Zou J . AKT1, AKT2 and AKT3-dependent cell survival is cell line-specific and knockdown of all three isoforms selectively induces apoptosis in 20 human tumor cell lines. Cancer Biol Ther. 2007; 6(5):755-62. DOI: 10.4161/cbt.6.5.3995. View

15.

Brantley E, Benveniste E . Signal transducer and activator of transcription-3: a molecular hub for signaling pathways in gliomas. Mol Cancer Res. 2008; 6(5):675-84. PMC: 3886801. DOI: 10.1158/1541-7786.MCR-07-2180. View

16.

Franke T . PI3K/Akt: getting it right matters. Oncogene. 2008; 27(50):6473-88. DOI: 10.1038/onc.2008.313. View

17.

Stupp R, Hegi M, Mason W, van den Bent M, Taphoorn M, Janzer R . Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009; 10(5):459-66. DOI: 10.1016/S1470-2045(09)70025-7. View

18.

Mizutani K, Roca H, Varsos Z, Pienta K . Possible mechanism of CCL2-induced Akt activation in prostate cancer cells. Anticancer Res. 2009; 29(8):3109-13. View

19.

Schwanzer-Pfeiffer D, Rossmanith E, Schildberger A, Falkenhagen D . Characterization of SVEP1, KIAA, and SRPX2 in an in vitro cell culture model of endotoxemia. Cell Immunol. 2010; 263(1):65-70. DOI: 10.1016/j.cellimm.2010.02.017. View

20.

Chautard E, Loubeau G, Tchirkov A, Chassagne J, Vermot-Desroches C, Morel L . Akt signaling pathway: a target for radiosensitizing human malignant glioma. Neuro Oncol. 2010; 12(5):434-43. PMC: 2940626. DOI: 10.1093/neuonc/nop059. View